Core Viewpoint - The company, Qianxin Biologics-B, has experienced a significant stock price increase following the announcement of its impressive financial performance for the first half of 2025, with a revenue growth of 359.69% year-on-year and a substantial reduction in losses [1][2] Financial Performance - Qianxin Biologics-B reported a revenue of RMB 206 million for the first half of 2025, marking a year-on-year increase of 359.69% [1] - The company incurred a loss of RMB 30.93 million, which represents an 83.11% decrease in losses compared to the previous year [1] Revenue Sources - The substantial revenue growth is attributed to income from external licensing project upfront payments, milestone payments, clinical research service fees, and CDMO (Contract Development and Manufacturing Organization) revenues [1] Market Position and Opportunities - Qianxin Biologics-B is recognized as a leader in the domestic self-immune innovative drug sector, with a strong foundation in this field [1] - The company’s mature pipeline is entering a monetization phase, enhancing its revenue-generating capabilities, while its innovative pipeline is poised for international expansion opportunities [1] Product Commercialization - The company has successfully commercialized its first product, a biosimilar of Ustekinumab named Seluxin, which received approval from the National Medical Products Administration for market launch in October 2024 [2] - As of June 2025, Qianxin Biologics-B has shipped over 60,000 units of Seluxin to its major shareholder, Huadong Medicine [2] Sales and Distribution - Huadong Medicine, which has a sales network covering over 30 provinces in China and employs more than 10,000 sales personnel, will facilitate the distribution of Qianxin Biologics-B's products, accelerating the commercialization process [2] - In the first half of the year, Seluxin has been prescribed in over 1,200 hospitals, indicating a gradual acceleration in market sales [2]
港股异动 | 荃信生物-B(02509)再涨超10% 公司成熟管线逐步迈入兑现期 赛乐信市场销售逐步提速